Novel inhibitors of Erm methyltransferases from NMR and parallel synthesis.

Hajduk PJ, Dinges J, Schkeryantz JM, Janowick D, Kaminski M, Tufano M, Augeri DJ, Petros A, Nienaber V, Zhong P, Hammond R, Coen M, Beutel B, Katz L, Fesik SW
J Med Chem. 1999 42 (19): 3852-9

PMID: 10508434 · DOI:10.1021/jm990293a

The Erm family of methyltransferases confers resistance to the macrolide-lincosamide-streptogramin type B (MLS) antibiotics through the methylation of 23S ribosomal RNA. Upon the methylation of RNA, the MLS antibiotics lose their ability to bind to the ribosome and exhibit their antibiotic activity. Using an NMR-based screen, we identified a series of triazine-containing compounds that bind weakly to ErmAM. These initial lead compounds were optimized by the parallel synthesis of a large number of analogues, resulting in compounds which inhibit the Erm-mediated methylation of rRNA in the low micromolar range. NMR and X-ray structures of enzyme/inhibitor complexes reveal that the inhibitors bind to the S-adenosylmethionine binding site on the Erm protein. These compounds represent novel methyltransferase inhibitors that serve as new leads for the reversal of Erm-mediated MLS antibiotic resistance.

MeSH Terms (13)

Binding Sites Crystallography, X-Ray Drug Design Drug Resistance, Microbial Ligands Magnetic Resonance Spectroscopy Methyltransferases Models, Chemical Models, Molecular Protein Conformation S-Adenosylmethionine Structure-Activity Relationship Triazines

Connections (1)

This publication is referenced by other Labnodes entities: